Modernas efforts to ensure significant supply of COVID-19 vaccines reaches pharmacies and points of care in the U.S.

9/21/2023

Immediately after receiving U.S. FDA approval, Moderna shipped millions of updated COVID-19 vaccines to our distributors across the United States. We are working to support these distributors to ensure that the significant supply of vaccines we have already provided to them continues to rapidly reach pharmacies and other points of care. Additional supply is being shipped daily as we continue to see high demand. Moderna continues to have an ample supply of updated COVID-19 vaccine available, with an additional 6 million doses available as of today.

Forward-Looking Statements

This statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Modernas efforts to ensure significant supply of COVID-19 vaccines reaches pharmacies and points of care, demand for COVID-19 vaccines, and the sufficiency of Modernas supply of vaccines. The forward-looking statements here are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Modernas control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading Risk Factors in Modernas Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SECs website at www.sec.gov. Except as required by law, Moderna disclaims any intention or
responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.